Wilms tumor

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search
Section editor
Liang.jpg
Wayne H. Liang, MD, MS
UAB
Birmingham, AL

LinkedIn
Social-twitter-icon.pngWayneLiangMD
3 regimens on this page
3 variants on this page


All lines of therapy

Dactinomycin monotherapy

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Wolff et al. 1968 Randomized (E) Single course of dactinomycin Seems to have superior RFS

Preceding treatment

Chemotherapy

6-week cycle for 3 cycles, then 3-month cycle for 4 cycles

References

  1. Wolff JA, Newton WA Jr, Krivit W, D'Angio GJ. Single versus multiple dose dactinomycin therapy of Wilms's tumor: a controlled co-operative study conducted by the Children's Cancer Study Group A (formerly Acute Leukemia Co-operative Chemotherapy Group A). N Engl J Med. 1968 Aug 8;279(6):290-4. link to original article PubMed
    1. Update: Wolff JA, D'Angio G, Hartmann J, Krivit W, Newton WA Jr. Long-term evaluation of single versus multiple courses of actinomycin D therapy of Wilms's tumor. N Engl J Med. 1974 Jan 10;290(2):84-6. link to original article contains verified protocol PubMed

Dactinomycin & Vincristine

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
de Kraker et al. 2004 (SIOP 93-01) Phase III (E) Prolonged chemotherapy Equivalent EFS
Pritchard-Jones et al. 2015 (SIOP WT 2001) Phase III (E) Dactinomycin, Doxorubicin, Vincristine Non-inferior EFS

Preceding treatment

Chemotherapy

References

  1. SIOP 93-01: de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, Godzinski J, Tournade MF; SIOP. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet. 2004 Oct 2-8;364(9441):1229-35. link to original article PubMed
  2. SIOP WT 2001: Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N; SIOP Renal Tumours Study Group. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015 Sep 19;386(9999):1156-64. Epub 2015 Jul 9. link to original article PubMed

Vincristine monotherapy

back to top

Regimen

Study Evidence
Sullivan et al. 1967 Pilot

Chemotherapy

Subsequent treatment

References

  1. Sullivan MP, Sutow WW, Cangir A, Taylor G. Vincristine sulfate in management of Wilms' tumor: replacement of preoperative irradiation by chemotherapy. JAMA. 1967 Oct 30;202(5):381-4. link to original article PubMed